Dollar Weakens as Middle East War Reshapes Global Rate Expectations 
Cyberattack on Stryker Triggers U.S. Government Warning Over Microsoft Intune Security 
China Holds Benchmark Loan Prime Rate Steady for Tenth Consecutive Month 
Elliott Investment Management Takes Activist Stake in Align Technology 
Israel Defies Trump's Warning, Launches New Strikes on Iran Amid Growing Global Energy Crisis 
Oil Prices Slide as U.S. Eyes Iranian Supply Relief Amid Middle East Tensions 
Malaysia Semiconductor Industry Eyes Helium Supply Risks Amid Middle East Conflict 
Iran-Israel War Escalates: Energy Infrastructure Attacks Shake Global Oil Markets 
Australia's February Jobs Data Sends Mixed Signals on Rate Outlook 
Super Micro Computer Shares Plunge After Co-Founder Charged in AI Chip Smuggling Case 
Asian Markets Rally on AI Optimism Ahead of Fed Decision 
Asian Currencies Hold Steady Amid Iran Conflict and Central Bank Decisions 
Genel Energy Reports FY25 Net Loss Below Fears, EBITDAX Beats Forecasts 
Global Flight Cancellations 2026: Airlines Suspend Routes Amid Middle East Crisis 
Oil Prices Surge Past $100 as U.S.-Israel War on Iran Threatens Global Energy Supply 
Japan's Parliament Backs Dovish BOJ Board Members, Raising Questions on Rate Hike Path 
Samsung Bets Big on AI-Driven Chip Demand in 2025 
Samsung Biologics and Samsung C&T are investing in Araris Switzerland-based biotech company. The former announced on Wednesday, April 12, that it would be joining in the series A funding round for the said Swiss firm.
Arais Biotech AG is a company that makes antibody-drug conjugate (ADC) technologies. This refers to a type of medicine formulated as a targeted therapy for the treatment of cancer.
Samsung Biologics is the contract manufacturing arm of the Samsung Group, and it has confirmed its participation in the funding round to secure a stake in the Swiss ADC company. As per The Korea Herald, it will be making its investments in Araris through Samsung Life Science Fund, which is being co-managed by Samsung Biologics and Samsung C&T.
The fund is said to be worth around KRW150 billion or $113 million, and it was set up in 2021 to support Samsung Biologics' bid to find new business opportunities in the global biotech industry.
It was said that the undisclosed amount of investment funds would be primarily used to back Araris in its works for the development of potential candidates for ADCs. The value of the fund was not shared with the public because of the agreements made between Samsung Biologics and Araris.
The South Korean biotech firm added that through this new investment, it is aiming to expand its ADC-related portfolio as well. It will also be able to actively participate in the production of ADC drugs through its partnership with Araris.
“Araris has the potential to develop best-in-class ADC therapies, and we see room for collaboration in the manufacturing and development of new drugs,” Samsung Biologics’ president and chief executive officer, John Rim, said in a statement.
Araris Biotech’s CEO and co-founder, Philipp Spycher, Ph.D., added, “We are pleased to receive this support from Samsung, as well as the recognition of the potential of our linker-payload toolbox and conjugation technology in such a quickly growing ADC field and we look forward to using these proceeds to further support our efforts in advancing our ADC candidates toward the clinic.”
